BioLineRx (NASDAQ:BLRX – Get Free Report) and Korro Bio (NASDAQ:KRRO – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, institutional ownership, earnings, profitability and valuation.
Institutional and Insider Ownership
1.6% of BioLineRx shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 1.1% of BioLineRx shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Volatility & Risk
BioLineRx has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 3.13, suggesting that its share price is 213% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for BioLineRx and Korro Bio, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
| Korro Bio | 1 | 2 | 6 | 3 | 2.92 |
Korro Bio has a consensus target price of $16.50, suggesting a potential upside of 74.79%. Given Korro Bio’s stronger consensus rating and higher probable upside, analysts clearly believe Korro Bio is more favorable than BioLineRx.
Earnings and Valuation
This table compares BioLineRx and Korro Bio”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BioLineRx | $1.18 million | 9.03 | -$1.17 million | ($1.69) | -1.27 |
| Korro Bio | $2.38 million | 58.36 | -$117.26 million | ($10.00) | -0.94 |
BioLineRx has higher earnings, but lower revenue than Korro Bio. BioLineRx is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BioLineRx and Korro Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BioLineRx | -502.08% | -34.80% | -18.27% |
| Korro Bio | N/A | -114.26% | -68.57% |
Summary
Korro Bio beats BioLineRx on 11 of the 15 factors compared between the two stocks.
About BioLineRx
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
About Korro Bio
Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.
